<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890656</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0166</org_study_id>
    <nct_id>NCT00890656</nct_id>
  </id_info>
  <brief_title>Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage</brief_title>
  <official_title>Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Enzon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if a special combination of chemotherapy
      drugs called &quot;augmented hyper-CVAD chemotherapy&quot; given over 6 to 8 months followed by monthly
      maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or
      lymphoblastic lymphoma. The safety of this therapy will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The augmented hyper-CVAD chemotherapy is a combination of chemotherapy drugs including
      cyclophosphamide, vincristine, adriamycin, dexamethasone, and pegaspargase given together for
      one &quot;course&quot; of treatment. It is called &quot;augmented&quot; because additional drugs are being added
      to the hyper-CVAD combination, which is the standard combination of chemotherapy drugs for
      the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma. This switches back
      and forth with a course of the chemotherapy drugs methotrexate and ara-C (also with
      vincristine, dexamethasone, and pegaspargase).

      Before treatment starts, you will have a physical exam, including blood (about 8 teaspoons)
      tests. You will also have a bone marrow sample taken; the sample will be taken through a
      large needle in the hipbone.

      All participants will receive 2 kinds of chemotherapy courses for a total of 8 courses.
      Chemotherapy courses will be given through a large vein by a central venous catheter (a
      plastic tube usually placed under the collarbone).

      During treatment, you will have a physical exam and give blood samples (about 1 tablespoon
      each) at least twice a week. A bone marrow sample will be repeated 2-3 weeks after the start
      of treatment to check the response, and later as needed.

      Course 1 will include cyclophosphamide given by vein over 2-3 hours every 12 hours. This will
      be given for 6 doses over 3 days (Days 1, 2 and 3). Adriamycin will be given by vein over 24
      hours on Day 4. Vincristine will be given by vein over 15 to 30 minutes on Days 1, 8, and 15.
      Dexamethasone (a steroid) will be given by mouth or by vein on Days 1 to 4 and 15-18.
      Pegaspargase will be given by vein over 1-2 hours on Day 1.

      G-CSF (growth colony stimulating factor) will be given starting 24 hours after each course of
      chemotherapy is finished (Day 5 or 6). It is given to help with rapid recovery of the normal
      bone marrow. G-CSF will be injected by vein or under the skin until the blood counts recover.

      Treatment to the brain will be given inside the spinal fluid (spinal tap) with ara-C and
      methotrexate on Days 2 and 7 of Courses 1 and 2 for a total of 4 treatments. This is done to
      decrease the risk that the leukemia will develop there.

      During Course 2, you will receive methotrexate by infusion over 24 hours on the first day and
      ara-C by vein at a high dose over 2 hours every 12 hours for 4 doses (Days 2 and 3). You will
      also receive vincristine (Days 1, 8, and 15), dexamethasone (Days 1-4 and 15-18), and
      pegaspargase (Day 5).

      Citrovorum factor (leucovorin), an antidote for side effects of methotrexate, will be given
      by vein or by mouth for 2-3 days (Day 2 and on). G-CSF will be given as in Course 1 (24 hours
      after the chemotherapy is finished). The treatment to the brain inside the spinal fluid will
      be given as in Course 1 on Days 2 and 7.

      The schedule of chemotherapy will switch between hyper-CVAD (Courses 3, 5, and 7) and
      methotrexate/ara-C (Courses 4, 6 and 8) to complete a total of 8 courses. After the 8
      courses, you will go on maintenance chemotherapy. This includes daily 6-mercaptopurine taken
      by mouth, weekly methotrexate by vein or mouth, monthly vincristine by vein, and prednisone
      by mouth for 5 days every month. Maintenance therapy will continue for one year.

      Treatment will be given on an inpatient or outpatient basis for the 8 intensive courses of
      chemotherapy, as indicated by your condition. The maintenance treatments may be given as an
      outpatient. Patients will be taken off study if the disease gets worse or if intolerable side
      effects occur.

      This is an investigational study. All of the drugs are commercially available. Their use
      together in this study is investigational. About 90 patients will take part in this study.
      All will be enrolled at UT MD Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Remission</measure>
    <time_frame>Response evaluated following first course at 14 -21 days and 1-2 weeks later to confirm response status (or at the time of hematologic recovery) and with visits every 2-3 courses.</time_frame>
    <description>Complete remission (CR) required a marrow with ≤ 5% blasts in a normo- or hypercellular marrow with an absolute neutrophil count (ANC) of ≥ 1 * 10^9/L and a platelet count of ≥ 100 * 10^9/L with complete resolution of all sites of extramedullary disease required.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CTX)</intervention_name>
    <description>300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg by vein (IV) weekly for 3: Days 1, 8, 15</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Oncovin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m^2 by vein (IV) over 24 hours</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Adriamycin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decadron</intervention_name>
    <description>80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Neupogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Rheumatrex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses</description>
    <arm_group_label>Augmented Hyper-CVAD</arm_group_label>
    <other_name>PEG asparaginase</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>Polyethylene Glycol Conjugated Lasparaginase-H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously treated acute lymphoblastic leukemia (ALL) (including Burkitt's lymphoma)
             or lymphoblastic lymphoma in relapse or primary refractory;

          -  No age restrictions;

          -  Zubrod performance status &lt;/= 3;

          -  Adequate liver (bilirubin &lt;/= 3mg/dl unless considered due to tumor) and renal
             function (creatinine &lt;/= 3mg/dl unless considered due to tumor);

          -  Adequate cardiac function (New York Heart Association (NYHA) &lt; III as assessed by
             history and physical examination)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan F. Faderl, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's website</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>July 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2011</results_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Hyper-CVAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 6/9/2003 to 10/12/2009. All patients registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Augmented Hyper-CVAD</title>
          <description>Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Augmented Hyper-CVAD</title>
          <description>Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="14" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Remission</title>
        <description>Complete remission (CR) required a marrow with ≤ 5% blasts in a normo- or hypercellular marrow with an absolute neutrophil count (ANC) of ≥ 1 * 10^9/L and a platelet count of ≥ 100 * 10^9/L with complete resolution of all sites of extramedullary disease required.</description>
        <time_frame>Response evaluated following first course at 14 -21 days and 1-2 weeks later to confirm response status (or at the time of hematologic recovery) and with visits every 2-3 courses.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Augmented Hyper-CVAD</title>
            <description>Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Remission</title>
          <description>Complete remission (CR) required a marrow with ≤ 5% blasts in a normo- or hypercellular marrow with an absolute neutrophil count (ANC) of ≥ 1 * 10^9/L and a platelet count of ≥ 100 * 10^9/L with complete resolution of all sites of extramedullary disease required.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 years, 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Augmented Hyper-CVAD</title>
          <description>Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI hemmorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stefan Fader, M.D./Associate Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713/745-4613</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

